Ruxolitinib is a JAK1/JAK2 kinase inhibitor mainly used to treat myeloproliferative tumors such as myelofibrosis and polycythemia vera, as well as immune related diseases such as graft-versus-host disease.

1. Main treatment for diseases

(1) Bone marrow fibrosis: used for the treatment of medium to high risk primary bone marrow fibrosis, post polycythemia vera bone marrow fibrosis, and post thrombocytopenia bone marrow fibrosis.

(2) Polycythemia vera: Used to treat patients with polycythemia vera who are resistant or intolerant to hydroxyurea.

(3) Graft-versus-host disease: used to treat steroid refractory acute graft-versus-host disease.

2 Applicable Population

(1) Bone marrow fibrosis patients: suitable for medium to high-risk bone marrow fibrosis patients, can improve splenomegaly and related symptoms.

(2) Patients with polycythemia vera: suitable for those who are ineffective or intolerant to traditional treatments.

(3) Hematopoietic stem cell transplantation patients: used to treat hormone refractory graft-versus-host disease.

3 Characteristics of Function

(1) Targeted therapy: Selective inhibition of JAK1/JAK2 kinases and regulation of abnormal signaling pathways.

(2) Symptom improvement: It can significantly reduce the volume of the spleen and improve symptoms related to bone marrow fibrosis.

(3) Dual function: It has both anti-tumor activity and immune regulatory effects.